Takamatsu, Hiroyuki http://orcid.org/0000-0001-9515-0017
Iida, Shinsuke
Shibayama, Hirohiko
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Suzuki, Kenshi
Funding for this research was provided by:
Janssen Pharmaceutical K.K.
Article History
Received: 31 October 2019
Revised: 7 January 2020
Accepted: 7 January 2020
First Online: 30 January 2020
Compliance with ethical standards
:
: Hiroyuki Takamatsu received honoraria from Janssen Pharmaceutical K.K., Celgene, Takeda, Ono Pharmaceutical, Bristol-Myers Squibb, Daiichi Sankyo Company, Fujimoto Pharmaceutical, and Sanofi; received research funds from Celgene, Ono Pharmaceutical, Bristol-Myers Squibb, and CSL Behring; and consulted for Janssen, Celgene, AbbVie, and Sanofi. Shinsuke Iida received honoraria and research funds from Janssen, Celgene, Ono, Takeda, Novartis, Daiichi Sankyo, and Bristol-Myers Squibb; and received research funds from Chugai, Sanofi, MSD, AbbVie, Gilead, Kyowa Hakko Kirin, Astellas, and Teijin Pharma. Hirohiko Shibayama received honoraria and research funds from Takeda, Ono, Eisai, Sumitomo Dainippon Pharma, Mundipharma, and Nippon Shinyaku; received honoraria from Janssen, Celgene, Novartis, Chugai, Kyowa Kirin, Otsuka, AstraZeneca, AbbVie, Daiichi Sankyo, Fujimoto, Sanofi, Bristol-Myers Squibb, and Pfizer; and received research funds from Astellas, Teijin, MSD, Shionogi, and Taiho. Kazuhiro Shibayama and Hiroshi Yamazaki are employees of Janssen Pharmaceutical K.K. Kenshi Suzuki received honoraria from Celgene, Takeda, Amgen, Novartis, Genesis Pharmaceuticals, and Janssen; and received honoraria and research funds from Bristol-Myers Squibb.